Myonexus Therapeutics Secures $2.5 Million Seed Financing to Clinically Advance Limb-Girdle Muscular Dystrophy (LGMD) Gene Therapies
MYO-101 Phase 1/2a systemic gene therapy trial for LGMD2E to begin in early 2018 New Albany, OH, 13 December 2017 – Myonexus Therapeutics, Inc. (Myonexus), a clinical-stage biotechnology company developing… Read more
Myonexus Therapeutics is a clinical stage gene therapy company developing first-ever gene treatments for multiple types of limb-girdle muscular dystrophy (LGMD), a group of progressive, debilitating musculoskeletal genetic diseases that… Read more
If ever there was a region where people are connected to cars, it’s Los Angeles. That’s why it’s particularly celebratory that GhostWave Inc., a startup radar technology company here in… Read more
No competition in sight? That isn’t a guarantee there won’t be competition tomorrow. Here are 5 situations when the first-mover might have a true advantage.
The main is packed for our Rev1 Resident Holiday Potluck! 🍽🥧🎄 https://t.co/VT70Nhf3dZ
- Friday Dec 15 - 5:42pm